该【肿瘤标志物及CT在非小细胞肺癌N2转移中的诊断价值 】是由【wz_198613】上传分享，文档一共【3】页，该文档可以免费在线阅读，需要了解更多关于【肿瘤标志物及CT在非小细胞肺癌N2转移中的诊断价值 】的内容，可以使用淘豆网的站内搜索功能，选择自己适合的文档，以下文字是截取该文章内的部分文字，如需要获得完整电子版，请下载此文档到您的设备，方便您编辑和打印。肿瘤标志物及CT在非小细胞肺癌N2转移中的诊断价值 Abstract: Lung cancer is one of the leading causes of cancer-related mortality worldwide, among which non-small cell lung cancer (NSCLC) is the most common type. N2 lymph node involvement in NSCLC is commonly used as an indication of disease progression and is associated with a poor prognosis. In this article, we discuss the use of tumor markers and CT scanning in the diagnosis and management of N2 lymph node metastases in NSCLC. Introduction: Non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths worldwide, with most patients diagnosed at an advanced stage of cancer. Lymph node metastasis is an important factor that affects the treatment and prognosis of NSCLC patients. N2 lymph node metastasis is an indication of advanced stage NSCLC, and its management remains challenging. The use of tumor markers and CT scanning in the diagnosis and management of N2 lymph node involvement in NSCLC has been investigated in many studies. This article aims to review the current literature on the use of these diagnostic tools in NSCLC patients with N2 lymph node metastasis. Tumor Markers in N2 Lymph Node Involvement in NSCLC: Tumor markers are substances that can be measured in the blood, tissue, or other body fluids of cancer patients. These markers may be produced directly by cancer cells or by the body in response to the presence of cancer cells. The use of tumor markers in the diagnosis and management of NSCLC has been widely studied. However, the value of tumor markers in N2 lymph node involvement in NSCLC is still under investigation. Several tumor markers have been evaluated for their diagnostic and prognostic value in NSCLC patients with N2 lymph node involvement. The most commonly used tumor markers in NSCLC are carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA 21-1), and neuron-specific enolase (NSE). CEA is a glycoprotein that is expressed in normal fetal colon tissue and is overexpressed in many cancers, including NSCLC. The diagnostic value of CEA in NSCLC has been shown to be limited in some studies. However, some studies have indicated that elevated preoperative serum CEA levels may be a predictor of poor survival in NSCLC patients with N2 lymph node involvement. CYFRA 21-1 is a tumor marker that is highly specific for lung cancer. Its diagnostic and prognostic value in NSCLC patients with N2 lymph node involvement has been investigated in several studies. Some studies have suggested that elevated preoperative serum CYFRA 21-1 levels are associated with a poor prognosis in NSCLC patients with N2 lymph node involvement. NSE is a tumor marker that is expressed in the nervous system and in some neuroendocrine tumors, including lung cancer. The use of NSE as a prognostic marker in NSCLC patients with N2 lymph node involvement has been investigated in some studies. A meta-analysis of these studies suggested that elevated preoperative serum NSE levels are associated with a poor prognosis in NSCLC patients with N2 lymph node involvement. These findings suggest that tumor markers may be helpful in predicting the prognosis of NSCLC patients with N2 lymph node involvement. However, the diagnostic value of tumor markers in NSCLC still needs to be further investigated. CT Scanning in N2 Lymph Node Involvement in NSCLC: CT scanning is a noninvasive imaging technique that is widely used in the diagnosis and management of NSCLC. It can provide detailed images of lung morphology and can detect lymph node involvement in NSCLC patients. The use of CT scanning in N2 lymph node involvement in NSCLC has been investigated in several studies. The accuracy of CT scanning in detecting N2 lymph node involvement in NSCLC varies widely. A meta-analysis of studies on the accuracy of CT scanning in detecting N2 lymph node involvement in NSCLC reported that the sensitivity of CT scanning ranged from 51% to 93%, while the specificity ranged from 69% to 100%. The findings of this meta-analysis suggest that CT scanning should not be used as the sole diagnostic tool for N2 lymph node involvement in NSCLC. The limitations of CT scanning in the diagnosis of N2 lymph node involvement in NSCLC include the false-negative results that are more likely to occur in small lymph nodes and those located near the hilum. Moreover, the presence of inflammatory and other benign diseases can lead to false-positive results. In conclusion, the use of tumor markers and CT scanning in the diagnosis and management of NSCLC patients with N2 lymph node involvement is still under investigation. Tumor markers may be helpful in predicting the prognosis of NSCLC patients with N2 lymph node involvement. However, the diagnostic value of tumor markers in NSCLC still needs to be further investigated. CT scanning is a valuable tool in detecting N2 lymph node involvement in NSCLC, but it should not be used as the sole diagnostic tool. Further research is needed to determine the optimal use of tumor markers and CT scanning in the management of NSCLC patients with N2 lymph node involvement.
